WSJ Brings Some Objectivity to the Media & Asks What the FDA’s Agenda is with Ivermectin

WSJ Brings Some Objectivity to the Media & Asks What the FDA's Agency is with Ivermectin?

In a breath of fresh air, a mainstream media opinion piece asks why the U.S. Food and Drug Administration (FDA) is denigrating a perfectly safe and effective drug? David R. Henderson and Charles L. Hopper wonder, "Why is the FDA attacking a safe, effective drug?" After all, the 'Gold Standard' agency is supported by science, yet it is truly on the offensive against a drug it approved in 1996. Of course, what that WSJ Op-Ed is referring to is the FDA's hit piece against ivermectin that TrialSite covered, where they declared in a special warning letter "you should not use ivermectin to treat or prevent COVID-19." And of course, the agency loaded the letter with scary terms such as "serious harm," "hospitalized," "dangerous," "seizures," and more. TrialSite sensed vested interests were now circling the wagons. That is, a low-cost, affordable approach couldn't be first in line—not in America at least.

Of the two scholars/authors, Mr. Henderson is a research fellow with the Hoover Institution at Stanford University. He previously served on President Regan's Council of Economic Advisors as a senior health economist. While Mr. Hooper currently serves as president of a pharmaceutical c...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee